2 active not recruiting, 2 completed. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Active not recruiting 2, Completed 2 |
Follow Myeloproliferative Neoplasm: new trials by email Literature Review of Myeloproliferative Neoplasm trials Research Report on Myeloproliferative Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk Ropeginterferon alfa-2b, Placebo - Primary Myelofibrosis, Myeloproliferative Neoplasm | Phase 3 | Active not recruiting | PharmaEssentia | 160 | 2025-07-18 | 2026-08-13 |
| Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome Asparaginase, Asparaginase Erwinia chrysanthemi, Cytarabine - Acute Myeloid Leukemia, Down Syndrome | Phase 3 | Active not recruiting | Children's Oncology Group | 280 | 2015-12-23 | 2026-08-19 |
| Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention tacrolimus, methotrexate, Mycophenolate mofetil - Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Completed | Case Comprehensive Cancer Center | 101 | 2014-07-07 | 2023-09-11 |
| Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Completed | Fred Hutchinson Cancer Center | 174 | 2010-11-01 | 2026-04-30 |
Myeloproliferative Disorders (4) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Hodgkin Disease (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2) · Multiple Myeloma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Down Syndrome (1) · Hematologic Neoplasms (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Prolymphocytic (1) · Leukemia, Prolymphocytic, T-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1)
Bone Marrow Diseases (4) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Leukemia (3) · Leukemia, Myeloid (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Blood Protein Disorders (2) · Cardiovascular Diseases (2) · Chronic Disease (2) · Disease Attributes (2) · Hemorrhagic Disorders (2) · Hemostatic Disorders (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2)
Mycophenolic Acid (2) · Asparaginase (1) · Cyclosporine (1) · Cyclosporins (1) · Cytarabine (1) · Daunorubicin (1) · Etoposide (1) · Leyk (1) · Methotrexate (1) · Mitoxantrone (1) · Peripheral Blood Stem Cell Transplantation (1) · Sirolimus (1) · Tacrolimus (1) · Thioguanine (1) · Whole-Body Irradiation (1)
Case Comprehensive Cancer Center (1) · Children's Oncology Group (1) · Fred Hutchinson Cancer Center (1) · PharmaEssentia (1)
United States (4) · Canada (2) · Australia (1) · China (1) · Denmark (1) · Germany (1) · Hong Kong (1) · Japan (1) · Jordan (1) · New Zealand (1) · Puerto Rico (1) · Saudi Arabia (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Betty Hamilton, MD (1) · Brenda Sandmaier (1) · Jason N Berman (1) · Toshiaki Sato, MD/PhD (1)
PMID 31248843, PMID 32499241, PMID 37352262, PMID 41124669
P01CA018029 (1), P30CA015704 (1), U10CA180886 (1)